QRG Capital Management Inc. Buys Shares of 1,101 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

QRG Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,101 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock worth $2,064,425,000 after purchasing an additional 30,608 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after acquiring an additional 364,021 shares in the last quarter. Northern Trust Corp increased its stake in shares of Alnylam Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 797,700 shares of the biopharmaceutical company’s stock valued at $141,273,000 after acquiring an additional 25,230 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Alnylam Pharmaceuticals by 12.9% during the third quarter. Ameriprise Financial Inc. now owns 706,200 shares of the biopharmaceutical company’s stock valued at $125,066,000 after acquiring an additional 80,862 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in Alnylam Pharmaceuticals by 2.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 688,228 shares of the biopharmaceutical company’s stock worth $121,885,000 after purchasing an additional 15,831 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ALNY. Chardan Capital reissued a “buy” rating and issued a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. HC Wainwright raised their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Wells Fargo & Company dropped their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a report on Friday, February 16th. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $216.19.

Check Out Our Latest Analysis on ALNY

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $149.62 on Wednesday. The business’s 50-day moving average is $149.33 and its 200-day moving average is $164.44. The company has a market capitalization of $18.93 billion, a price-to-earnings ratio of -55.83 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.40) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Further Reading

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.